Monocyte chemotactic protein-4 (MCP-4/CCL-13) and CC chemokine receptor 3 (CCR3) in the sputum of asthmatic children by El-Gamal, Yehia M et al.
Egypt J Pediatr Allergy Immunol 2008; 6(1): 13-25. 
13 
 
Monocyte chemotactic protein-4 (MCP-4/CCL-13) and CC chemokine 
receptor 3 (CCR3) in the sputum of asthmatic children  
 
INTRODUCTION 
Atopic and non-atopic asthma are characterized by 
chronic inflammation and local tissue eosinophilia. 
Atopic asthma is characterized by a 50-fold 
increase in the number of eosinophils relative to 
neutrophils in the bronchial mucosa. This is the 
result of the cumulative and sequential effects of 
variable increases in selective eosinophil versus 
neutrophil migration occurring at a number of 
stages in the life cycle of the eosinophil. Such 
eosinophils contain an army of chemicals 
implicated in the damage to airway epithelium and 
is related to the observed changes in airway 
function. It is thus likely that understanding the 
mechanisms of eosinophil recruitment to the airway 
will offer new therapeutic approaches for the 
treatment of this disease1. 
The mechanisms that regulate the selective 
accumulation, activation, and retention of airway 
eosinophils and T cells are areas of active 
investigation. Present evidences suggest that 
recruitment of eosinophils and T cells into sites of 
inflammation is a multistep process involving 
leukocyte-endothelial interactions through adhesion 
molecules and local generation of type 2 T helper 
(Th2) cytokines and some chemoattractants that 
direct cell migration from the vascular compartment 
into the inflamed airways2. 
The effects of Th2 cytokines, such as interleukin 
(IL)-4, IL-5, IL-9, and IL-13, account for virtually 
all the pathophysiological manifestations of allergy 
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Background: Monocyte chemotactic protein-4 (MCP-4/CCL-13) is a potent 
chemoattractant to eosinophils, monocytes and lymphocytes.  
Objective: We aimed to investigate MCP-4 and its CC chemokine receptor 3 
(CCR3) expression on cells of induced sputum during acute asthma 
exacerbation. 
Methods: Immunohistochemistry was used to assess MCP-4 and CCR3 
expression on induced sputum cells of 30 children during asthma 
exacerbation and 20 healthy matched controls. Patients were divided into 
three groups according to exacerbation severity; mild, moderate and severe 
(n = 10 for each). Patients were followed until quiescence, when sputum was 
re-examined.  
Results: MCP-4 and CCR3 were expressed on eosinophils and monocytes. 
Lymphocytes expressed only MCP-4. The percentages of sputum total cells, 
eosinophils and lymphocytes expressing MCP-4 and/or CCR3 were 
significantly higher during asthma exacerbation than in controls and 
negatively correlated with peak expiratory flow rate, whereas that of 
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MCP-4 and CCR3 decreased. Sputum eosinophil percentage correlated 
positively with the percentage of eosinophils expressing MCP-4 and CCR3 
(r = 0.69, p < 0.0001; r = 0.62, p < 0.001, respectively). The percentage of 
sputum eosinophils expressing MCP-4 correlated positively with that of cells 
expressing CCR3 (r = 0.95, p < 0.0001). 
Conclusion: The expression of MCP-4 and CCR3 on sputum cells increases 
during acute asthma exacerbation and this increase correlates with 
exacerbation severity, and it decreases during remission. Modification of 
their expression could be a potential target for asthma therapy.  
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and asthma. Moreover, both Th2 cells and the 
effector cells present in the areas of allergic 
inflammation, (basophils, mast cells and 
eosinophils), express chemoattractant receptors. 
Therefore, chemokine/chemoreceptor interactions 
are responsible for the recruitment of these effector 
cells, and play a critical role in the allergen-induced 
recruitment of Th2 cells in the target tissues of 
allergic inflammation3. 
Chemokines are a superfamily of proteins that 
are potent chemoattractants for leukocytes in 
allergic inflammation. The CC chemokine receptor 
3 (CCR3) is the common receptor on eosinophils 
for cysteine/cysteine (CC) chemokines such as 
CCL24/eotaxin-2, CCL26/eotaxin-3, CCL13/ 
monocyte chemotactic protein-4, (MCP-4), MCP-3, 
and RANTES (Regulated Upon Activation, Normal 
T Cell Expressed and Secreted), which are 
important for the release of eosinophils from bone 
marrow into the circulation and the recruitment of 
eosinophils from blood into tissues4. CCR3 is the 
receptor that mediates the majority of the eosinophil 
chemotactic effects. CCR3 is present on cell types 
associated with allergy such as the eosinophils, 
basophils, mast cells and CD4 (+) T helper 2 cells5. 
MCP-4 has been shown in vitro to potently 
induce eosinophil chemotaxis as well as initiate 
several other pro-inflammatory activities such as 
integrin activation, lipid mediator biosynthesis and 
degranulation. Ligand binding and chemotaxis 
experiments demonstrated that the G-protein 
coupled-receptor cloned from eosinophils, CCR3, 
was responsible for producing MCP-4 selectivity 
profile identical to that of eosinophils. Together 
these studies strongly suggest a central role for 
MCP-4/CCR3 interaction in eosinophil trafficking. 
CCR3 has also been found on in vitro derived Th2 
cells and on T-cells co-localizing with eosinophils 
in diseased tissue, thus revealing a possible 
pathogenic mechanism for T-cell recruitment into 
the airways6.  
In asthmatic airways, MCP-4 has been localized 
immunohistochemically and by in-situ 
hybridization analysis to eosinophils, macrophages, 
epithelial and endothelial cells. After allergen 
challenge, MCP-4 is expressed on the epithelial 
surface of the airways in sites at which eosinophils 
accumulate. The established selective chemotactic 
and activating effects of MCP-4 on eosinophils and 
the association of eosinophils with asthma activity 
and severity suggest that MCP-4 is an important 
mediator in acute asthma7. Therefore, this study 
attempted to determine the percentage of different 
sputum cells expressing MCP-4 and its receptor 
CCR3 in induced sputum of asthmatic children 
during exacerbation and quiescence and in relation 
to asthma severity. MCP-4 antagonism and/or 
blockade of CCR3 on eosinophils may represent a 




This follow-up, case-control study comprised 30 
asthmatic children as a stratified non-random 
sample recruited from the Pediatric Allergy and 
Immunology Clinic and Emergency Department of 
Ain Shams University Children’s Hospital while 
presenting with an acute asthmatic exacerbation. 
They were 17 (57%) males and 13 (43%) females, 
their ages ranged from 5 to 15 years with a mean 
age of 10.72 ± 3.26 years. It also included 20 
healthy children without personal or family history 
of asthma or other atopic conditions as a control 
group. They were 12 (60%) males and 8 (40%) 
females, their ages ranged from 6 to 14 years with a 
mean age of 10.4 ± 2.44 years. An informed 
consent was obtained from the parents or caregivers 
of each child before enrollment. 
Children were subjected to thorough history 
taking and clinical examination. The diagnosis of 
asthma had been based on the clinical symptoms 
and signs of episodic wheezing, chest tightness and 
dyspnea that improved at least partially after 
bronchodilator therapy. Patients were excluded 
from the study if they had respiratory infection. 
None of the patients had chest radiograph or 
sputum culture evidence of pulmonary bacterial 
infection and none received antibiotics during the 
study period. 
Patients were studied within 24 hours of the start 
of an acute asthma exacerbation (defined by 
increasing cough, wheezing, dyspnea and nocturnal 
symptoms). Children were classified into three 
groups according to the severity of acute asthma 
attacks based on clinical data and the Global 
Initiative for Asthma Guidelines8,9. In this 
classification, Peak Expiratory Flow Rate (PEFR) 
was measured using Mini-Wright Peak Flow Meter 
(Clement Clarke International Ltd., Sales Office 
Armed House, Edinburgh Way, Harlow, UK). The 
PEFR of each patient was compared with normal 
population and % predicted was calculated. Ten 
children (7 males and 3 females; mean age: 10.75 ± 
3.74 years) presented with mild acute asthma 
exacerbation, 10 children (6 males and 4 females; 
mean age: 11.5 ± 3.63 years) with moderate 
exacerbation, and the remaining 10 children (4 
males and 6 females; mean age: 10.9 ± 2.38 years) 
had severe asthma exacerbation.  
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Based on the criteria of asthma grading10, the 
clinical severity of the recruited asthmatics during 
quiescence was classified into intermittent asthma 
in four children (13%) and mild and moderate 
persistent asthma in 26 children (87%).  
Patients received quick relief medications to 
relieve acute bronchoconstriction as oral β2 agonists 
(terbutaline; 0.1-0.2 mg/kg/day) in 4 patients 
(13%), or inhaled β2 agonists (salbutamol) in 26 
patients (87%). Two patients (6.6%) had history of 
need of short courses of oral corticosteroids for 3-
10 days during previous acute exacerbations. As 
regards long-term controller medications; 10 
(33.5%) patients were receiving inhaled 
corticosteroids, 7 (23%) were receiving sustained-
release theophylline (6-18 mg/kg/day), and 10 
(33.5%) patients were receiving both drugs. Three 




1. Complete blood counts: applying Coulter Counter 
T66OA (Coulter Electronics Ltd, UK). 
2. Serum total IgE: by ELISA technique (BioCheck, 
Inc 323 Vintage Park Dr. Foster City, CA 94404). 
3. Immunohistochemical analysis of MCP-4/CCL-
13 and CCR3 on sputum cells: 
• Sputum collection: Subjects under study were 
selected above 5 years of age so that adequate 
sputum samples can be obtained spontaneously 
when required. Sputum was induced only when it 
could not be produced spontaneously. All 
subjects were premedicated with inhaled 
salbutamol given by nebulizer in a dose of (0.15 
mg/kg/dose) 30 minutes before sputum induction. 
To minimize contamination with saliva and 
postnasal drip, subjects were asked to rinse their 
mouths and blow their noses before induction 
and, wherever possible, before expectoration. 
Subjects inhaled 3% hypertonic saline solution 
aerosols generated by Farmasol compressor 
nebulizer. Hypertonic saline was inhaled 10-15 
minutes according to the severity of asthma until 
an adequate volume of sputum was 
expectorated11. 
• Sputum examination: Sputum sample volumes 
were recorded. Sputum samples containing <20% 
of contaminating squamous cells were considered 
suitable for analysis, they were processed 
immediately by a modification of the technique 
described by Pizzichini et al 12. Sputum was 
treated by adding 2 mL of Hanks balanced salt 
solution containing 0.1% dithiothreitol, then 
vortexed for 2 to 3 min to homogenize the 
sample. Two mL of phosphate-buffered solution 
was added to stop the action of dithiothreitol, and 
then the suspension was centrifuged at 300g for 
10 min. The cell pellet was resuspended in 
phosphate-buffered solution, and total cell counts 
of leukocytes using hemocytometer were 
determined. Differential cell counts of 
eosinophils, macrophages, lymphocytes, and 
neutrophils were counted microscopically. 
Eosinophils in sputum were expressed as absolute 
count and percentage of leukocytes. For 
immunocytochemistry, coded cytospins were 
fixed in a solution of acetone: methanol (2:3), air 
dried, and stored at -20˚C until further assessment 
of MCP-4, and CCR3. 
• Sputum was stained by immunoenzymatic/ 
immunohistochemical (IHC) analysis techniques 
that allow the visualization of tissue (cell) 
antigens. These techniques are based on the 
immunoreactivity of antibodies and the chemical 
properties of enzymes or enzyme complexes, 
which react with colorless substrate-chromogens 
to produce a colored product13.  The DAKO 
LSAB+ kit (DakoCytomation, Inc. 6392 Via Real 
Carpinteria, California 93013 USA) is based on a 
modified labeled avidin-biotin (LAB) technique 
in which a biotinylated secondary antibody forms 
a complex with peroxidase-conjugated steptavidin 
molecules. In the assay, endogenous peroxidase 
activity can be quenched by first incubating the 
specimens for five minutes in 3% hydrogen 
peroxide. Then specimens were incubated with an 
appropriately characterized and diluted rabbit, 
mouse or goat primary antibody, followed by 
sequential incubations with biotinylated link 
antibody and peroxidase-labelled steptavidin. 
Staining was completed after incubation with 
substrate-chromagen solution. This was followed 
by counter staining with hematoxylin. Examining 
the slides was done as soon as possible. Counting 
of immunoreactivity among different types of 
cells (eosinophils, macrophages, lymphocytes, 
and neutrophils) was done in at least 400 cells 
(using more than one slide in cases of low total 
leukocyte counts. 
 
Statistical Analysis  
All statistical analyses were carried out using SPSS 
(Statistical Package for the Social Science) version 
9.02 for Windows system. Data were expressed as 
mean ± standard deviation (SD). As regards 
parametric data, ANOVA test (F-value) was used 
for comparison between more than 2 groups and the 
student’s “t” test of significance to compare 
between 2 groups. Paired-t test was applied to 
compare between the same group in two repeated 
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measurements. For non-parametric data Kruskall-
Wallis test (H value) was used for comparison 
between more than 2 groups, and the Mann-
Whitney test (Z-value) was used to compare 
between two groups, whereas, comparison between 
the same group in two repeated measurements was 
done via Wilcoxon-signed rank test. The Pearson’s 
correlation coefficient (r) was used to interrelate the 





Total and differential cell counts in the sputum 
of the studied groups (table 1) 
Children during acute asthma exacerbation had 
significantly higher sputum total cell, eosinophil, 
lymphocyte, and neutrophil counts than controls; 
however, their sputum monocyte count was 
significantly lower than controls (p<0.01 for all). 
During quiescence, sputum monocyte and total cell 
counts were significantly lower, while sputum 
lymphocyte and neutrophil counts were 
significantly higher as compared to controls. 
Sputum eosinophil counts were statistically 
comparable (p>0.05). Patients during asthma 
exacerbations had higher sputum total cell, 
eosinophil and neutrophil counts than during 
remission. Sputum monocyte and lymphocyte 
counts were statistically comparable during 
exacerbation and quiescence. 
MCP-4 and CCR3 were expressed on 
eosinophils and monocytes. Lymphocytes 
expressed only MCP-4. Percentages of sputum total 
cells, eosinophils, monocytes, and lymphocytes 
expressing MCP-4 and percentages of sputum total 
cells, eosinophils, and monocytes expressing CCR3 
were significantly higher in patients during both 
asthma exacerbation and quiescence than controls 
(p<0.01 for all). Percentage of total and individual 
sputum cells expressing MCP-4 and CCR3 during 
asthma exacerbation was significantly higher than 
in-between attacks (p<0.01). 
 
Percentage of sputum cells expressing MCP-
4/CCL-13 and CCR3 in relation to severity of 
acute asthma exacerbations, and asthma grading 
between exacerbations (tables 2 & 3; fig. 1) 
The absolute blood and sputum eosinophil counts 
were significantly higher in patients with severe 
asthmatic attacks than those with mild and 
moderate attacks. Percentage of sputum total cells, 
eosinophils, monocytes and lymphocytes 
expressing MCP-4; and total cells and eosinophils 
expressing CCR3 were significantly higher in 
patients with severe than those with mild and 
moderate exacerbation. Monocytes expressing 
CCR3 were significantly lower in patients with 
severe attacks than those with mild attacks 
(p<0.01). The percentages of lymphocytes and 
monocytes expressing MCP-4, and the percentages 
of total cells and monocytes expressing CCR3 were 
statistically comparable in the mild and moderate 
groups (table 2; fig. 1). 
Total serum IgE, absolute blood eosinophil 
count, and the total and differential sputum cell 
counts were statistically comparable in intermittent 
and persistent asthma. Patients with mild persistent 
asthma had higher percentage of total cells and 
monocytes expressing MCP-4, and eosinophils 
expressing CCR3 than those with intermittent 
asthma. Children with moderate persistent asthma 
had higher percentage of eosinophils expressing 
CCR3 than those with intermittent asthma (table 3). 
 
Percentage of sputum cells expressing MCP-
4/CCL-13 and CCR3 in relation to therapy and 
asthma variables (table 4; fig. 2 & 3):  
The type of controller medication could not be 
related to the total serum IgE. However, it affected 
blood and sputum eosinophils counts where the 
highest count was found in children receiving 
inhaled steroid therapy. There was a significant 
difference concerning percentages of monocytes 
expressing MCP-4 and percentages of total cells 
expressing CCR3 in response to controller 
medications (table 4). 
There was a significant positive correlation 
between blood and sputum eosinophils counts (r = 
0.73; p<0.05). Sputum eosinophil percentage was 
positively correlated to the percentage of 
eosinophils expressing MCP-4 and CCR3 during 
acute attacks (r = 0.69, p<0.0001; r = 0.62, p<0.001, 
respectively; fig. 2). Moreover, the percentages of 
sputum eosinophils expressing MCP-4 and those 
expressing CCR3 were positively correlated (r = 
0.95, p<0.0001; fig. 3). There were significant 
negative correlations between PEFR and percentage 
of sputum total cells, eosinophils, lymphocytes, and 
monocytes expressing MCP-4 on the one hand and 
the percentage of total cells and eosinophils 
expressing CCR3 on the other. 
The immunohistochemical staining of MCP-
4/CCL-13 and CCR3 in sputum eosinophils during 
and in-between acute asthmatic attacks are shown 
in figures 4 and 5 respectively. 
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Table 1. Total and differential cell counts and percentage of cells expressing monocyte 
chemotactic protein-4 (MCP-4/CCL-13) and CC chemokine receptor 3 (CCR3) in the sputum 
of the studied groups. Values are given as mean ± SD. 
Sputum total and differential cell count (cells/106 X mL)
8.6 **9.93 **15.29 **2.55 ± 0.514.63 ± 0.968.90 ± 2.19Monocytes
10.6 **9.65 **12.06 **2.45 ± 0.608 ± 3.0637.4 ± 15.8Eosinophils
6.62 **3.52 **9.49 **1.96 ± 0.352.41 ± 0.567.77 ± 3.33Total cells
Percentage of cells expressing CC Chemokine Receptor 3 (CCR3)
7.92 **5.99 **9.84 **2.75 ± 0.555.1 ± 2.0415.7 ± 7.17Lymphocytes
16.4 **7.16 **14.05 **2.90 ± 0.726.5 ± 2.6121.47 ± 7.1Monocytes
4.76 **5.33 **5.94§ **2.55 ± 0.514.57 ± 1.9819.6 ± 11.5Eosinophils
8.66 **5.79 **10.63 **2.36 ± 0.523.66 ± 1.0610.81 ± 4.3Total cells
Percentage of cells expressing Monocyte Chemotactic Protein-4 (MCP-4/CCL-13)
2.21 *4.56 **8.63 **0.5 ± 0.120.85 ± 0.381.89 ± 0.86Neutrophils
1.12.1§ *3.67§ **0.16 ± 0.070.29 ± 0.190.35 ± 0.17Lymphocytes
1.2110.9 **4.64§ **2.15 ± 0.280.99 ± 0.461.37 ± 0.17Monocytes
4.92 **0.78§5.04§ **0.14 ± 0.840.12 ± 0.120.48 ± 0.31Eosinophils
2.4 *2.49 *3.94 **2.92 ± 0.392.26 ± 0.924.14 ± 1.62Total count
Asthma         
exacerbation 
vs. quiescence




t or z §
Asthma         
exacerbation 
vs. controls
t or z §
Controls
(n= 20)
Asthma       
quiescence
(n= 30)



























































































































































































Figure 1. Percentage of sputum cells expressing monocyte chemotactic protein-4 (MCP-4/CCL-13) (fig. 
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Table 2. Blood eosinophils, serum total IgE and percentage of sputum cells expressing 
monocyte chemotactic protein-4 (MCP-4/CCL-13) and CC chemokine receptor 3 
(CCR3) according to the degree of severity of acute asthmatic attacks. Values are given 
as mean ± SD. 
Monocytes 10.2 ± 1.75 9.1 ± 0.99 7.4 ± 2.63 1.65 3.8 ** 0.89
Eosinophils 20.9 ± 3.67 34.5 ± 3.47 56.8 ± 7.35 4.22 § ** 5.12 § ** 5.44 § **
Total cells 4.46 ± 0.47 6.9 ± 1.09 11.96 ± 1.34 3.1 4.1 ** 4.58 **
Percentage of cells expressing CCR3
Lymphocytes 14.2 ± 4.78 10.4 ± 4.2 22.5 ± 6.35 1.23 4.2 ** 4.52 **
Monocytes 16.3 ± 5.6 20.4 ± 3.89 27.7 ± 6.77 1.24 3.21 ** 2.9 **
Eosinophils 8.5 ± 4.25 16.2 ± 2.39 34.2 ± 4.54 3.4 § ** 3.1 § ** 4.4§ **
Total cells 6.25 ± 1.48 10.2 ± 1.55 15.99 ± 1.42 5.11** 3.5 ** 4.02 **
Percentage of cells expressing MCP-4/CCL-13
Neutrophils 1.88 ± 0.81 1.65 ± 1.04 2.13 ± 0.73 1.4 § 1.2 § 0.1 §
Lymphocytes 0.26 ± 0.14 0.38 ± 0.2 0.41 ± 0.12 0.52 § 0.73 § 1.1 §
Monocytes 1.17 ± 0.66 1.4 ± 0.55 1.54 ± 0.85 0.75 § 0.11 § 1.1 §
Eosinophils 0.22 ± 0.07 0.38 ± 0.15 0.85 ± 0.23 1.92 § * 4.1§ ** 3.32 § **
Total cells 3.54 ± 1.51 3.95 ± 1.57 4.92 ± 1.62 1.2 1.9 * 0.9




0.21 ± 0.15 0.33 ± 0.22 0.59 ± 0.21 1.72 § 3.3 § * 2.3 § *
IgE 













t or Z §
Severe
vs. Mild
t or Z §
Severe
vs. Moderate
t or Z §
 
*: Significant difference (p < 0.05); **: Highly significant difference (p<0.01); §: Mann-
Whitney test  
 
 
















































































































Figure 2. Positive correlations between the percentage of sputum cells expressing monocyte chemotactic 
protein-4 (MCP-4/CCL-13) (fig. 2A) and CC chemokine receptor 3 (CCR3) (fig. 2B) and the percentage of 
sputum eosinophils among asthmatic children during acute exacerbations. 
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Table 3. Blood eosinophils, serum total IgE and percentage of sputum cells expressing 
monocyte chemotactic protein-4 (MCP-4/CCL-13) and CC chemokine receptor 3 
(CCR3) between asthmatic attacks. Values are given as mean ± SD 
Monocytes 5.25 ± 0.5 4.54 ± 1.1 4.54 ± 0.9 0.38 0.39 0.05
Eosinophils 6.7 ± 0.5 8.15 ± 2.8 8.23 ± 3.75 1.9 * 1.95 * 0.51
Total cells 2.9 ± 0.5 2.35 ± 0.5 2.3 ± 0.58 0.4 0.31 0.01
Percentage of cells expressing CCR3
Lymphocytes 5.3 ± 3.3 5.5 ± 1.3 4.6 ± 2.3 0.06 § 0.27 § 0.46 §
Monocytes 4.5 ± 2.5 7.6 ± 2.6 6 ± 2.24 2.37 § * 1.8 § 0.58 §
Eosinophils 4 ± 1.4 4.62 ± 2.2 4.7 ± 1.9 0.11 0.16 0.04
Total cells 2.75 ± 0.96 4.12 ± 1 3.47 ± 0.96 1.93 * 1.6 1.3
Percentage of cells expressing MCP-4/CCL-13
Neutrophils 0.72 ± 0.38 0.78 ± 0.3 0.96 ± 0.39 0.02 § 0.06 § 0.36 §
Lymphocytes 0.21 ± 0.14 0.24 ± 0.2 0.35 ± 0.19 0.07 § 0.24 § 0.34 §
Monocytes 0.92 ± 0.25 0.9 ± 0.4 1.1 ± 0.57 0.05 § 0.07 § 0.8 §
Eosinophils 0.09 ± 0.04 0.1 ± 0.05 0.15 ± 0.1 0.09 § 0.21§ 0.11§
Total cells 1.95 ± 0.72 2.03 ± 0.8 2.58 ± 1.04 0.51 § 0.56 0.24
Sputum total and differential cell count (cells/106 X mL)
Blood eosinophils
(cells X 109/mL) 0.11 ± 0.08 0.14 ± 0.1 0.15 ± 0.09 0.33 § 0.5 § 0.41 §
IgE
(IU/ml) 821 ± 748 708 ± 537 1823 ±1274 1.1 § 1.44 § 1.3 §
t or z§ t or z§ t or z§




















*: Significant difference (p < 0.05); §: Mann-Whitney test  
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Figure 3. Positive correlation between the percentage of 
sputum eosinophils expressing monocyte chemotactic protein-
4 (MCP-4/CCL-13) and CC chemokine receptor 3 (CCR3) 
among asthmatic children during acute exacerbations. 
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Table 4. Blood eosinophils, serum total IgE and percentage of sputum cells 
expressing monocyte chemotactic protein-4 (MCP-4/CCL-13) and CC 
chemokine receptor 3 (CCR3) according to therapeutic intervention. Values are 
given as mean ± SD. 
Monocytes 5.7 ± 1 4.4 ± 1 4.8 ± 0.5 4.5 ± 0.9 1.53
Eosinophils 7.7 ± 2 7.6 ± 1.9 10.6 ± 5.6 7.4 ± 2.3 1.27 §
Total cells 3.2 ± 0.3 2.3 ± 0.1 2 ± 0.2 2.4 ± 0.6 3.3 *
Percentage of cells expressing CCR3
Lymphocytes 7.3 ± 2.5 4.4 ± 1 4.8 ± 0.4 5 ± 2.4 1.5
Monocytes 5.3 ± 4 7 ± 2.5 9.6 ± 0.9 5.5 ± 1.9 9.6 § *
Eosinophils 4.3 ± 0.6 3.6 ± 1 6 ± 3 4.6 ± 1.9 3.2 §
Total cells 3.7 ± 2 3.8 ± 1 4 ± 0.5 3.4 ± 0.9 2.3 §
Percentage of cells expressing MCP-4/CCL-13
Neutrophils 1 ± 0.73 1.8 ± 1.2 2.27 ± 0.8 1.9 ± 0.66 3.54 §
Lymphocytes 0.23 ± 0.14 0.22 ± 0.19 0.4± 0.16 0.4 ± 0.14 8.16 §
Monocytes 1.27 ± 0.63 1 ± 0.61 1.16 ± 0.5 1.6 ± 0.73 4.12 §
Eosinophils 0.28 ± 0.14 0.23 ± 0.09 0.65 ± 0.28 0.58 ± 0.34 9.8 § *
Total cells 2.93 ± 1.58 3.26 ± 1.75 4.48 ± 1.49 4.67 ± 1.45 5.33 §




0.28 ± 0.03 0.14 ± 0.13 0.5 ± 0.26 0.46 ± 0.25 10.67 § *
IgE























*: Significant difference (p < 0.05); §: Kruskall -Wallis test  
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Figure 4.  Immunohistochemical staining of MCP-4/CCL-13 in 
sputum eosinophils of asthmatic children during and between acute 
exacerbations. 
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Activity Remission  
Figure 5.  Immunohistochemical staining of CCR3 in sputum 






MCP-4 expression is known to be increased in 
asthmatic airways where it is induced by proallergic 
cytokines. Chemokine expression in broncho-
alveolar lavage (BAL) and bronchial biopsy 
specimens has been demonstrated in asthmatic 
airways, but not thoroughly investigated in induced 
sputum of asthmatic children. Moreover, the 
mechanisms responsible for cellular recruitment of 
eosinophils in the small airways of asthmatic 
individuals remain to be clarified1. Therefore, we 
sought to determine the expression of MCP-4 and 
its receptor CCR3 on induced sputum cells of 
asthmatic children. 
During acute asthma exacerbation, the 
percentage of total and differential sputum cells 
expressing MCP-4 and CCR3 were significantly 
higher in comparison to the corresponding values in 
the stable state and in comparison to controls. These 
data conform with several other reports7,13-23. Taha 
et al.18 reported increased MCP-4 immunoreactivity 
in induced sputum of asthmatic patients in 
comparison to control subjects. In addition, Kalayci 
et al.7 reported that MCP-4 is a systemically 
expressed biomarker of asthma. MCP-4 mRNA and 
protein were significantly upregulated in the 
epithelium and submucosa of bronchial biopsies 
and in BAL cells of patients with asthma compared 
with normal subjects14-17,20. The results of this study 
may reflect the up regulation of CCR3 and its 
ligand, MCP-4, in allergic inflammation, presenting 
potentially useful markers for the presence of atopic 
response. 
CCR3 had been identified as a major CC 
chemokine receptor on eosinophils22. Its expression 
had been demonstrated on basophils13 and Th2-type 
T cells20 suggesting possible roles for CCR3 in the 
genesis and maintenance of allergic inflammation. 
MCP-4 induces migration of eosinophils through at 
least two receptors; CCR2b and CCR3, however, 
CCR3 is the selective receptor on eosinophils and 
to a lesser extent on lymphocytes for MCP-421. In 
this respect, Fujisawa and associates24 proved that 
MCP-4-induced eosinophil degranulation is 
mediated only through CCR3. The concordant 
expression of CCR3 and its ligand in the airway, 
contributes to bronchial eosinophilia in atopic 
asthma. MCP-4 might play a role in release of 
eosinophils from bone marrow into the circulation 
and the recruitment of eosinophils from blood into 
the airways to contribute to the small airways and 
peripheral lung inflammation in asthma. MCP-
4/CCR3 may be therefore a major target for anti-
inflammatory drug development. 
When asthmatic children were followed-up to 
stability, sustained elevation of the percentage of 
total and differential sputum cells expressing MCP-
4 and CCR3 in comparison to control values was 
found. This could be due to the ongoing process of 
sub-clinical allergic inflammation in the lungs of 
persistent asthmatics during clinical remission. 
Moreover, patients with mild persistent asthma had 
higher percentage of total cells and monocytes 
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expressing MCP-4, and eosinophils expressing 
CCR3 than those with intermittent asthma. Children 
with moderate persistent asthma had higher 
percentage of eosinophils expressing CCR3 than 
those with intermittent asthma. This might reflect 
the ongoing inflammatory allergic process with 
persistent infiltration of airways by inflammatory 
cells particularly lymphocytes even after subsidence 
of exacerbations. These cells release mediators that 
in turn recruit more and more inflammatory cells in 
a vicious circle manner. Such observations could be 
indicative of the continued exposure to triggering 
factors and/or the need for more intensive anti-
inflammatory treatment. Therefore, we suggest that 
MCP-4/CCR3 could be used as markers of the 
ongoing airway inflammatory activity. 
CCR3 and its ligand have been suggested as 
useful objective markers for the severity of asthma 
exacerbations. The percentage of sputum total cells, 
eosinophils, monocytes and lymphocytes 
expressing MCP-4, and total cells and eosinophils 
expressing CCR3 were significantly higher in 
patients with severe than those with mild and 
moderate exacerbations. Furthermore, CCR3 and 
MCP-4 expression were observed to be inversely 
correlated with PEFR. This probably reflects 
excessive influx of inflammatory cells in acute 
severe attacks causing injury to bronchial mucosa, 
mediating bronchospasm and culminating in 
bronchial obstruction and impaired lung function 
and in turn the severity of acute exacerbations. 
Noteworthy, Kalayci and coworkers7 found that 
systemic expression of MCP-4 was significantly 
higher in patients with chronic stable asthma than in 
normal subjects, and even higher in matched 
subjects experiencing acute severe asthma 
exacerbation. They suggested that a systemically 
detectable MCP-4 level is an important independent 
marker of the inflammatory state that occurs in 
asthma. Furthermore, the observation that patients 
with an acute exacerbation of asthma had higher 
plasma levels of MCP-4 than did matched subjects 
with chronic-stable asthma suggests that the plasma 
MCP-4 is further increased in active disease or, 
alternatively, that individuals with higher MCP-4 
levels were more prone to suffer severe asthma 
exacerbation and may benefit from abrogation of 
MCP-4. 
In this study, absolute blood and sputum 
eosinophil counts were significantly higher in 
patients with severe than those with moderate and 
mild asthma exacerbations. Many studies13,18,21 had 
suggested a strong association among eosinophil 
numbers, their state of activation, and the severity 
of asthma. Eosinophils are thought to be an 
important effector cell involved in the induction of 
bronchial mucosal damage by the release of 
cytotoxic proteins, reactive oxygen metabolites, and 
proinflammatory and profibrotic cytokines1. 
The positive correlation between the percentages 
of sputum eosinophils expressing MCP-4 and those 
expressing CCR3 during exacerbations probably 
reflects excessive MCP-4 production from 
bronchial epithelial cells during bursts of bronchial 
asthma.  
In the present study, sputum eosinophil 
percentage was positively correlated to the 
percentage of eosinophils expressing MCP-4 and 
CCR3 during acute attacks. A significant 
association between the concentrations of MCP-4 
and eosinophil numbers in BAL fluid had been 
reported19,24. These findings suggest that MCP-4 
regulates eosinophil trafficking into the airways of 
asthmatic children in a coordinated manner. In 
contrast, Taha et al 18 did not find such a 
correlation. 
Human blood eosinophils express high levels of 
CCR3, which is responsible for both migration and 
degranulation 1.  Liu et al. 25 studied blood and BAL 
cells that were obtained from allergic subjects 48 
hours after segmental bronchoprovocation with 
antigen. They reported that there was a high 
expression of CCR3 (nearly 100%) on blood 
eosinophils and this expression did not change after 
segmental bronchoprovocation with allergen. 
Furthermore, expression of CCR3 was significantly 
correlated with the percentage of eosinophils in 
BAL fluid at 48 hours. These data provide evidence 
that as eosinophils are recruited to the airway 
during an allergic inflammatory response, they 
demonstrate different phenotypic characteristics 
manifested, in part, by a different profile of 
chemokine receptors. These changes might provide 
insight into the differential regulation of eosinophil 
recruitment and activation in allergic airway 
disease.  
The effect of inhaled corticosteroid therapy on 
CCR3 and its ligand was found by some 
investigators to be highly impressive8,26. However, 
in the current study, the effect of steroids was 
restricted to the increase in percentage of sputum 
monocytes expressing MCP-4 and a generalized 
decrease in total sputum cells expressing CCR3. 
Fukakusa et al.26 demonstrated a dual nature of 
corticosteroids. Although inhaled corticosteroids 
down regulates TH 2 cytokines and reduces the 
number of eotaxin MCP-3, and MCP-4 mRNA-
positive cells in the epithelium and subepithelium, 
they can also up regulate the expression of other 
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chemokines, including IL-8, IFNγ-inducible protein 
10 (IP-10), and MCP-2.  
Moreover, the percentage of blood eosinophils 
and sputum eosinophils were higher in asthmatic 
patients receiving inhaled steroids, whether alone or 
with long-acting theophylline, than those not 
receiving them. The increase in blood and sputum 
eosinophils may be related to the severity of asthma 
not to the effect of steroids. Hughes27 reported that 
subjects taking inhaled corticosteroids did not differ 
significantly from those on β2-agonists ± cromolyn 
with respect to circulating blood eosinophils. 
Noteworthy, the mechanism of the glucocorticoids 
effect is multifactorial involving inhibition of both 
T-cell function and eosinophil recruitment. Inhaled 
corticosteroids have been shown to decrease the 
number of eosinophils but to increase neutrophils. 
Corticosteroids reduce the number of CD3-positive 
T cells and major basic protein-positive 
eosinophils26. Interpretation of the results of this 
study may be complicated by the existence of 
additional variables such as disease state, subject 
variability and the small number of children 
recruited in the study. Therefore, further studies 
involving higher number of patients with similar 
asthma severity or following up patients before and 
after treatment with different asthma therapies are 
recommended. 
Eosinophils represent one of the main effector 
cell populations of allergic airway inflammation 
and allergic bronchial asthma. Their infiltration 
correlates with many characteristics of the disease, 
including airway hyperresponsiveness and 
increased mucus production. CCR-3 is the principle 
chemokine receptor involved in eosinophil 
attraction into inflamed tissue. Therefore, 
antagonizing CCR-3 could be a novel promising 
approach toward asthma therapy. 
YM-355179 is a novel, selective, and orally 
available CCR3 antagonist with therapeutic 
potential for treating eosinophil-related allergic 
inflammatory diseases. Oral administration of YM-
355179 (1 mg/kg) inhibited chemokine-induced 
shape change of whole blood eosinophils in 
monkeys. It also inhibited eosinophil degranulation 
and eosinophil infiltration into airways after 
segmental bronchoprovocation with eotaxin5,28. In 
addition, blocking CCR3 on eosinophils, with a 
monoclonal antibody, completely abolished 
eosinophil responses to these chemokines. The 
reduction in eosinophil infiltration was 
accompanied by normalization of airway 
hyperresponsiveness and prevention of goblet cell 
hyperplasia, indicating reduced mucus production. 
Furthermore, antagonizing CCR-3 prevented airway 
remodeling as defined by subepithelial fibrosis and 
increased accumulation of myofibrocytes in the 
airway wall of chronically challenged model29. 
In conclusion, MCP-4 and CCR3 expression on 
induced sputum cells were up regulated during 
acute asthma exacerbation and this increase was 
related to exacerbation severity. MCP-4 and its 
ligand might contribute to  small airways and 
peripheral lung inflammation in asthma. They are 
expected to have biological significance in the 
regulation of eosinophil recruitment into the 
asthmatic bronchi leading to development of the 
pathophysiological endpoint of asthma, the airway 
hyperreactivity. In addition, they seem to be 
involved in the establishment and maintenance of 
chronic inflammation of the airways. We 
recommended the use of induced sputum as a non-
invasive technique in studying chemokine 
expression in children with bronchial asthma. 
Setting pediatric reference ranges for MCP-4 in 
biological fluids, and exploring CCR3 expression 
on different immune cells involved in atopy are 
worthwhile. Moreover, the effect of MCP-4 and 
CCR3 antagonism should be considered attractive 
targets for specific anti-inflammatory therapy. 
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